Search - tctmd.com

Displaying 1 - 20 of 99

Sort: Relevancy | Date

News Opinion CV Team Dispatch

March 2026 Dispatch for the CV Team

L.A. McKeown

March 26, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

L.A. McKeown

March 04, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Cardiac Damage Starts Early When There’s Family History of Cardiometabolic Disease

Caitlin E. Cox

December 18, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

Healthcare Expenses Increase After GLP-1 Prescription

L.A. McKeown

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Presentation TCT India 2025

Challenging Cases - Masters

Presenter: Saurabh Gupta

July 27, 2025

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Daily News

Taxing Sugar-Sweetened Drinks Modestly Impacts BMI

L.A. McKeown

February 05, 2025

News Daily News

Misleading Statements Common in Online Ads for Compounded GLP-1s

L.A. McKeown

January 20, 2025

News Daily News

Global Commission Proposes ‘Radical’ Overhaul of Obesity Diagnosis

L.A. McKeown

January 14, 2025

News Daily News

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

L.A. McKeown

January 10, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Advertisement

March 2026 Dispatch for the CV Team

What’s Going to Be Hot at ACC 2026

CRT 2026: What to Expect in Washington, DC

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

Cardiac Damage Starts Early When There’s Family History of Cardiometabolic Disease

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Healthcare Expenses Increase After GLP-1 Prescription

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Challenging Cases - Masters

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Taxing Sugar-Sweetened Drinks Modestly Impacts BMI

Misleading Statements Common in Online Ads for Compounded GLP-1s

Global Commission Proposes ‘Radical’ Overhaul of Obesity Diagnosis

Global Study Shows Sugary Drinks Boosting Diabetes and CVD at Alarming Rates

Top General Cardiology and Prevention News of 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content